1	Original Article
2	
3	Increased adiposity is protective for breast and prostate cancer: a Mendelian
4	randomisation study using up to 132,413 breast cancer cases and 85,907 prostate
5	cancer cases
6	
7	<sup>1</sup> H. A. Amin, <sup>1</sup> P. Kaewsri, <sup>1</sup> A. M. Yiorkas, <sup>1</sup> H. Cooke, <sup>1</sup> A. I. Blakemore, and <sup>1</sup> F. Drenos
8	
9	<sup>1</sup> Department of Life Sciences, College of Health and Life Sciences, Brunel University
10	London, Uxbridge, United Kingdom
11	
12	Corresponding Author:
13	
14	Dr Fotios Drenos
15	
16	Department of Life Sciences
17	College of Health and Life Sciences
18	Brunel University London
19	Kingston Lane
20	Uxbridge
21	Middlesex
22	UB8 3PH
23	United Kingdom
24	
25	+44 (0)1895 266951
26	Fotios.Drenos@brunel.ac.uk
27	

#### 29 ABSTRACT

30

#### Background 31

32 Breast and prostate cancer are the first and second most common types of cancer in

- women and men, respectively. A recent campaign by Cancer Research UK emphasised 33
- obesity as being a causal risk factor for cancer, although previously published evidence 34
- is heterogenous. We aimed to explore the causal effect of adiposity on breast and 35
- prostate cancer risk in the UK Biobank (UKB), a large prospective cohort study, and 36
- 37 published data.
- 38

39 Methods

- 40 We used Mendelian randomisation (MR) to assess the causal effect of body mass index
- 41 (BMI), body fat percentage (BFP), waist circumference (WC), hip circumference (HC),
- 42 and waist-to-hip ratio (WHR) on breast and prostate cancer risk.
- 43
- Results 44
- 45 We obtained estimates (odds ratios, OR, per SD unit increase) of the causal effect of the
- adiposity measures on breast and prostate cancer risk. BMI and HC decrease the risk of 46
- 47 breast cancer (OR 0.776 [95% Cls 0.661-0.91] and OR 0.781 [95% Cls 0.649-0.94],
- respectively). WC, BFP, and BMI decrease the risk of prostate cancer (OR 0.602 [95% CIs 48
- 49 0.439-0.825], OR 0.629 [95% CIs 0.414-0.956], and OR 0.695 [95% CIs 0.553-0.874],
- respectively). The protective effect of adiposity on prostate cancer risk is enhanced in 50
- men who are exposed to potentially hazardous substances at work, and the association 51
- between BMI and breast cancer is confounded by variables associated with general 52 health.
- 53
- 54

### 55 Conclusions

- In conclusion, increasing adiposity is causally protective for breast and prostate cancer 56
- 57 and the effects in prostate cancer may, at least partly, be due to the safe storage of
- 58 chemicals in adipose cells. It is necessary to explore the mechanisms through which
- 59 adiposity may protect against or be a risk factor for cancer, to identify how the latter
- can be minimised without sacrificing the former, and to base public health campaigns 60
- around sound evidence. 61
- 62

# 63 KEYWORDS

64

- 65 Obesity; Breast cancer; Prostate cancer; Mendelian randomization; Persistent organic
- 66 pollutants.

## 68 **HIGHLIGHTS**

69		
70	•	Previously published evidence regarding the effect of adiposity on prostate and
71		breast cancer risk is heterogenous
72	•	Increasing BMI and hip circumference decrease the risk of breast cancer in
73		women
74	•	Increasing waist circumference, body fat percentage, and BMI decrease the risk
75		of prostate cancer
76	•	The protective effect of adiposity on prostate cancer is stronger in men who are
77		exposed to carcinogens at work
78	•	Public health campaigns need to target the negative aspects of adiposity whilst
79		preserving the positive aspects
80		
81		

### 82 INTRODUCTION

83

Breast and prostate cancer are the most common and second most common types of cancer diagnosed worldwide in men and women, respectively.<sup>1</sup> In 2010, the combined cost of breast and prostate cancer to the NHS was £664 million.<sup>2</sup> The number of cases are expected to rapidly increase and, by 2040, are estimated to be 20.2% higher for breast cancer and 38.5% higher for prostate cancer in comparison to 2018.<sup>1</sup> Both cancer types are preventable in many cases, making robust identification of their modifiable risk factors important.

91

A recent campaign by Cancer Research UK<sup>3</sup> has emphasised obesity as being a causal 92 risk factor for cancer comparable to smoking. It has been proposed that the metabolic 93 environment in obese people is conducive to oncogenic transformation.<sup>4</sup> However, 94 previously published evidence on the relationship between adiposity and breast and 95 prostate cancer does not consistently support this view.<sup>5-7</sup> It has been suggested that 96 adiposity is a risk factor for breast cancer in post-menopausal women,<sup>8</sup> but not in pre-97 98 menopausal women.<sup>9</sup> The effect of BMI on prostate cancer risk is reported to depend upon the aggressiveness of the tumour.<sup>10</sup> 99

100

Assessment of what exposures are causal is not trivial: "correlation is not causation". 101 The vast majority of studies carried out to examine the impact of adiposity on breast 102 and prostate cancer risk are observational and may be susceptible to confounding. 103 104 Mendelian randomisation (MR) is a method that uses genetic variants associated with an exposure of interest, but not with any confounders, to assess the causal effect of the 105 genetically predicted exposure on an outcome. In order for the method to provide 106 reliable estimates of the causal effect, it is also assumed that the chosen instruments 107 are not related to the outcome of interest independently of the exposure (this is known 108 109 as the "exclusion restriction" assumption).

110

With this work, we aim to explore the causal effect of adiposity on breast and prostate cancer risk in the UK Biobank (UKB), a large prospective cohort study, and published data.<sup>11-15</sup> We also aim to use the rich phenotype data collected as part of the UKB study to identify variables, if any, that may explain the observed relationship between adiposity and breast and prostate cancer risk.

5

#### SUBJECTS AND METHODS 117

118

### Population and Study Design 119

120

The UK Biobank (UKB) is a large prospective cohort study including information and 121 biological samples for approximately 500,000 individuals, recruited between 2006 and 122 2011. The 22 UKB assessment centres throughout England, Wales and Scotland, 123 collected baseline data from the participants in the form of questionnaires, physical and 124 cognitive tests and blood and urine samples.<sup>16</sup> The age range of the participants at the 125 time of enrolment in the study was between 40 and 69 years of age, with a mean age of 126 56.5 years. Males represent 45.6% of the sample. The use of the data for this project 127 128 was approved by the UKB (application 44566).

129

#### 130 Genotyping

131

488,377 individuals had been genotyped for up to 812,428 variants using DNA extracted 132 from blood samples on either the UKB Axiom array (438,427 participants) or the UK

133

BiLEVE Axiom array (49,950 participants). Variants that did not pass standard guality 134

control checks were excluded.<sup>17</sup> These included tests for the presence batch effects, 135

plate effects, sex effects and array effects, as well as any departures from Hardy-136

Weinberg Equilibrium using a p-value threshold of  $10^{-12}$ . Variants with a minor allele 137

frequency of <0.01 were also excluded. For imputed variants, all variants with an INFO 138

score of <0.8 were excluded from the analysis. 139

140

Sample genotyping quality control metrics were provided by UKB.<sup>17</sup> Samples were 141 excluded from the analysis if they were outliers for missingness and/or PC-corrected 142 heterozygosity and/or if they had any sex chromosome aneuploidies as well as if the 143 genetically inferred sex differed from the reported sex. Samples which did not have a 144 genetically determined White British ancestry were also excluded. A list of related 145 146 individuals was also provided by UKB and one individual from each related pair was 147 excluded at random.

148

### Phenotypes 149

151 We used data collected at baseline for body mass index (BMI, UKB field 21001), body fat

152 percentage (BFP, UKB field 23099) from bio-impedance, waist circumference (WC, UKB

- 153 field 48) and hip circumference (HC, UKB field 49). We calculated waist-to-hip ratio
- 154 (WHR) by dividing WC by HC. The variables were standardised to a mean of 0 and a
- 155 variance of 1.
- 156
- We used cancer diagnoses information from the 1970s onward obtained from linkage tonational cancer registries and health records (see
- 159 http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/CancerLinkage.pdf). Breast
- 160 cancer cases are defined as females who have an ICD-10 code C50 recorded at least
- 161 once (UKB field 40006). Prostate cancer cases are defined as males who have an ICD-10
- 162 code C61 recorded at least once (UKB field 40006). Females who have an ICD-10 code
- 163 D05, for in situ carcinoma of the breast, without a C50 breast cancer entry were
- removed from the sample. Similarly, males with an ICD-10 code D075, for carcinoma in
- situ of prostate, without a C61 prostate cancer diagnosis were also removed from thesample.
- 167
- 168 Menopause information for females was obtained through the reported age of
- 169 menopause information collected (UKB field 3581). This information was compared to
- 170 the age of first breast cancer diagnosis to identify the pre- and post-menopausal cases.
- 171 For women who did not have breast cancer, we used their menopause status at
- baseline to stratify them into pre- and post-menopausal.
- 173

Exposure to chemicals was based on occupation exposure information. A participant
was considered to have been exposed to chemicals frequently if they answered "Often"

- and/or "Sometimes" at least once for any of the following UKB fields: 22609 (Workplace
- very dusty); 22610 (Workplace full of chemical or other fumes); 22611 (Workplace had a
- 178 lot of cigarette smoke from other people smoking); 22612 (Worked with materials
- 179 containing asbestos); 22613 (Worked with paints, thinners or glues); 22614 (Worked
- 180 with pesticides); and 22615 (Workplace had a lot of diesel exhaust).
- 181
- 182 <u>Statistical Analyses</u>
- 183

We used R 3.6.1<sup>18</sup> to carry out analyses and generate plots, unless stated otherwise. For 184 the observational analyses, we removed prevalent cases and regressed the exposures 185 (i.e. BMI, BFP, WC, HC, and WHR) against prostate and breast cancer cases using a 186 logistic regression adjusting for age at baseline. We then generated genetic risk scores 187 (GRS) for the exposures in PLINK 1.9<sup>19</sup> using sex-specific summary statistics from 188 GIANT<sup>14, 15</sup> and Lu et al.<sup>11</sup> We tested the association between the GRSs and prostate and 189 breast cancer adjusting for the first four principal components (PCs) for the genetic 190 variability of the genome, age at baseline, and genotyping array used. We stratified the 191 sample by menopause and by chemical exposure and repeated this analysis. We used 192 the GRSs as instruments to carry out MR as described elsewhere.<sup>20</sup> We adjusted for the 193 first four genetic PCs and the genotyping array used in the first step and adjusted for 194 195 age at baseline in the second step.

196

197 Two-sample MR and multivariate MR analyses were carried out using the TwoSampleMR R package.<sup>21</sup> All of the independent loci used as instruments in the two-198 sample MR analyses were based on sex-stratified GWAS meta-analyses of European 199 200 ancestry. For BFP, we used the sex-stratified summary statistics for 10 variants obtained from Lu et al.<sup>11</sup> We obtained sex-stratified summary statistics from GIANT for waist-to-201 hip ratio, waist circumference, hip circumference, <sup>14</sup> and BMI.<sup>15</sup> If a variant did not reach 202 genome-wide statistical significance for men or women in the sex-stratified analyses in 203 204 the external data, it was excluded. We used the same information for the multivariate two-sample MR with the exception of BFP sex-stratified summary statistics, which were 205 not available, and the estimates were generated using UKB data instead. The outcome 206 data used were from Michailidou et al.<sup>12</sup> and Shumacher et al.,<sup>13</sup> which are the meta-207 analysis of breast cancer (122,977 cases, 105,974 controls) and the meta-analysis of 208 prostate cancer (79,194 cases, 61,112 controls), respectively. 209

210

To identify the potential confounders, we developed an algorithm that used a step-wise procedure to identify any variables in the UKB that may be responsible for the observed positive association between BMI and incident breast cancer cases. Only variables with more than 1000 non-missing observations associated with both BMI and breast cancer (p<0.05) were considered. Categorical phenotypes were converted to separate binary variables. Our algorithm selected variables based on the extent to which they minimised the effect size of BMI on breast cancer.

218

### 219 **RESULTS**

220

After QC, we had 151,940 males and 174,410 females remaining in the sample. Table 1 summarises their age, BMI at baseline, and lifetime smoking status.

223

224 We first sought to examine the observational effect of the adiposity measures (i.e. BMI,

BFP, WC, HC, and WHR) on the risk of breast and prostate cancer. We only used incident

226 cases to avoid a previous cancer diagnosis affecting any of the measures considered. We

found that, in our sample, each of the adiposity measures are associated with an

increased risk of breast cancer but a decreased risk of prostate cancer (Figure 1 &

229 Supplementary Table 1).

230

231 We generated GRSs for each of the adiposity measures, for males and females 232 separately, to use as instrumental variables (Supplementary Table 2). We regressed the 233 outcomes on each of these GRSs to determine whether males and females who are genetically predisposed to increased adiposity are at a decreased or increased risk of 234 235 developing prostate or breast cancer, respectively. We found that, in our sample, a 236 genetic predisposition to increased BMI, WC, and HC is associated with a decreased risk 237 of breast cancer in women, and that a genetic predisposition to increased BMI and WC is associated with a decreased risk of prostate cancer (Supplementary Figures 1-3 & 238 239 Supplementary Table 3).

240

We found that the associations between the GRSs for BMI, WC, and HC and breast 241 cancer were present even after adjusting for BMI, WC, and HC, respectively 242 (Supplementary Table 4). This suggests that these GRSs violate the exclusion restriction 243 assumption, i.e. the genetic instrument may affect the outcome independently of the 244 exposure, end the estimated causal effect may be biased. We addressed this issue by 245 confirming our one-sample MR results using the MR Egger method, which is robust even 246 247 when the exclusion restriction assumption is violated. We found that the GRS for BMI 248 was not associated with prostate cancer independently of BMI. However, the GRS for 249 WC was associated with prostate risk independently of WC (Supplementary Table 4), so the estimate of the causal effect of WC on prostate cancer risk obtained in the UKB may 250 251 also be biased.

252

We obtained estimates (odds ratios, OR, per SD unit increase) of the causal effect of the 253 254 adiposity measures on breast and prostate cancer using one-sample MR (Figures 2 & 3). We found that increased BMI and HC decreased the risk of breast cancer (OR 0.776 255  $[95\% \text{ Cls } 0.661 \text{ to } 0.91, \text{ p} = 1.79 \times 10^{-3}]$  and OR 0.781  $[95\% \text{ Cls } 0.649 \text{ to } 0.94, \text{ p} = 9.02 \times 10^{-3}]$ 256 <sup>3</sup>], respectively), and increased WC, BFP, and BMI decreased the risk of prostate cancer 257  $(OR \ 0.602 \ [95\% \ Cls \ 0.439 \ to \ 0.825, \ p = 1.61 \times 10^{-3}], \ OR \ 0.629 \ [95\% \ Cls \ 0.414 \ to \ 0.956, \ p = 1.61 \times 10^{-3}]$ 258 0.0301], and OR 0.695 [95% CIs 0.553 to 0.874,  $p = 1.89 \times 10^{3}$ ], respectively). 259 260 We sought to replicate our findings using external outcome summary statistics from 261 meta-analyses of 122,977 breast cancer cases<sup>12</sup> and 79,194 prostate cancer cases, <sup>13</sup> and 262 external exposure summary statistics from Lu et al.<sup>11</sup> and GIANT.<sup>14, 15</sup> We used two-263 264 sample MR to assess the causal effect of adiposity measures on breast and prostate 265 cancer risk (Tables 2 & 3). We found that increased BMI, WC, HC, and BFP are causally 266 protective for breast cancer using the inverse variance weighted method 267 (Supplementary Figure 4). The p-values of the intercept from the MR Egger method 268 suggest that the instruments used for BMI, WC, and HC may be pleiotropic, but the 269 causal estimates generated using MR Egger show that increased BMI, WC, and HC are still protective for breast cancer when any bias from pleiotropy is taken into account 270 271 (Table 2). We also found that BMI was the only adiposity measure causally protective for prostate cancer (Supplementary Figure 5). 272 273 We next performed multivariable MR to identify whether the protective effects of 274 increased BMI, WC, HC, and BFP on breast cancer risk are independent of each other 275 276 (Supplementary Table 6). We found that BMI and BFP were still protective for breast 277 cancer independently of the other measures, but WC and HC were not. 278 We hypothesised that the protective effect of adiposity may be due to adipose tissue 279 280 absorbing and safely storing environmental carcinogens. We, therefore, stratified our

- sample, based on self-reported exposure to dust and/or chemicals and/or fumes at
- work and repeated the analyses. We found that the protective effect of increasing
- adiposity on prostate cancer was stronger in men who reported that they were
- frequently exposed to potentially hazardous substances at work in comparison those
- 285 who were not. This is particularly evident for BMI and WC, where the confidence

intervals of the frequently and infrequently exposed strata do not overlap (Figure 3). Wedid not observe the same pattern in women (Figure 2).

288

289 We stratified women based on their menopause status at breast cancer diagnosis (or at

290 baseline for controls). We did not find evidence that the protective effect of adiposity

291 was different between pre- and post-menopausal women, with the estimates between

the groups being similar and having overlapping confidence intervals (Figure 2).

293

294 We used a stepwise procedure to identify any confounding variables that might explain

295 the opposite direction of effects estimated by the observational and MR associations of

BMI with risk of breast cancer. Supplementary Table 7 lists the fields that were both

associated with incident breast cancer risk and attenuated the detrimental effect of

BMI. The ln(OR) of breast cancer per SD unit increase in BMI is reduced tenfold when

these variables (namely ankle spacing width, frequency of stair climbing, amount of

300 moderate physical activity, macular degeneration, and leukocyte count) are added to

301 the model, but it does not decrease below zero. It is possible that the variables our

302 algorithm selects may be associated with a missing or currently unknown higher order

303 variable that may explain the discrepancy between the observed and causal associations

304 between BMI and risk of breast cancer.

### 306 DISCUSSION

307

We sought to assess the causal effects of increased adiposity on the risk of breast and 308 309 prostate cancer. We found that increased adiposity measures were observationally associated with a lower risk of prostate cancer, but with an increased risk of female 310 breast cancer. When we assessed the causal effects of the adiposity measures on the 311 risk of prostate and breast cancer using a one sample MR, we found that increased BMI, 312 BFP, and WC were causally protective for prostate cancer, and increased BMI and HC 313 were causally protective for breast cancer. Using a two sample MR with previously 314 315 published data, BMI was further confirmed as causally protective for both outcomes, and HC was confirmed as causally protective for breast cancer. Multivariable MR 316 317 analyses suggest that BFP and BMI are the independent drivers of these protective 318 associations between the adiposity measures and breast cancer. When testing whether 319 or not these protective effects could be attributed to the safe storage of chemicals in 320 adipose tissue, we showed that the causally protective effect on prostate cancer was 321 consistently stronger, though not always statistically significant, in those reporting 322 exposure to potentially carcinogenic substances at work. However, no such association was evident for breast cancer. When we attempted to identify the confounders 323 324 responsible for the observed detrimental association between increasing BMI and breast cancer, we found a number of variables that may be involved, but these are of a 325 326 currently uncertain clinical significance. 327

In this work, we found that increases in all of the adiposity measures we tested were 328 observationally associated with a higher number of breast cancer cases. In this respect, 329 the UK Biobank is in agreement with a previously published large meta-analysis of 126 330 studies finding the same association.<sup>22</sup> The inverse associations between the adiposity 331 measures and prostate cancer were more surprising. Here the evidence are more 332 heterogeneous, as illustrated by a recent large scale meta-analysis,<sup>10</sup> which found an 333 334 overall null association between BMI and prostate cancer, but found an inverse 335 association between BMI and prostate specific antigen concentrations. Furthermore, a number of well powered studies<sup>23, 24</sup> have also identified an inverse association 336 between BMI and prostate cancer, so our results in the UK Biobank are, therefore, not 337 unusual. Furthermore, increased adiposity is only protective for low grade prostate 338 cancer,<sup>10</sup> the prostate cancer cases in the UKB are likely to be low grade due to the age 339

of the sample, and this may further explain why we found an inverse observational

341 relationship between adiposity and prostate cancer risk.

342

343 Since observational studies cannot directly provide information on cause and effect relationships, we carried out MR analyses to see whether the associations we found 344 were causal. We found that adiposity was causally protective for breast cancer and our 345 results are similar to those reported by Guo *et al.*<sup>6</sup> using the same study but with a 346 lower number of cases. Observationally, adiposity has been reported to be protective 347 for pre-menopausal breast cancer,<sup>9</sup> but our results suggest that this protective effect 348 349 can only be established for post-menopausal breast cancer cases, though the absence of 350 a protective effect in pre-menopausal breast cancer cases may be due to the smaller 351 number of cases in this cohort. We show that the causal estimate of the protective 352 effect of body fat percentage on breast cancer is independent of the causal effect of 353 BMI, and it is more reliable because we find no evidence that the GRS for BFP is 354 pleiotropic. We also found evidence that the association between BMI and breast cancer is confounded, and that the confounder is likely to be either a non-observed 355 356 variable or a higher order variable combining different existing variables in the data. We also found that BMI is causally protective for prostate cancer in the UK Biobank dataset. 357 and this is supported by our analysis of external data. Davies *et al.*<sup>7</sup> report no causal 358 effect of BMI on prostate cancer, but this may be due to lack of statistical power 359 360 because they used a smaller number of cases (20,848 vs. 79,194). 361

There is previously published evidence which suggests that adipose tissue may play a 362 role in safely storing harmful chemicals.<sup>25</sup> Persistent organic pollutant (POP) 363 concentrations increase by 2-4% per kg of weight loss and remain elevated for up to 12 364 months after a weight loss intervention.<sup>26</sup> We hypothesised that the protective effect of 365 increasing adiposity on prostate and breast cancer risk might be explained by its ability 366 367 to sequester potentially carcinogenic substances. Our results, which show that the 368 protective effect was enhanced in men reporting more frequent exposure to potentially 369 carcinogenic substances at work, support our hypothesis in prostate cancer. The same 370 effect was not observed in female breast cancer, which may be due to an insufficient number of cases or due to a more complex underlying mechanism. 371 372

The direction of the observational association between BMI and breast cancer is 373 opposite to that of the causal effect, which suggests that the former is confounded. We 374 found that variables relating to physical activity (i.e. frequency of stair climbing and 375 moderate physical activity) may be one source of confounding and this is supported by 376 the fact that increased physical activity is protective for breast cancer<sup>27</sup>. Our algorithm 377 also selected macular degeneration (an eye disease for which increasing age is the 378 strongest risk factor and circulating lipids have also been involved),<sup>28</sup> ankle width (which 379 might represent swelling of the lower extremities - symptoms of diabetes and 380 cardiovascular disease), and leukocyte count (a marker of systemic inflammation).<sup>29</sup> 381 These variables are likely to represent a currently undefined higher order variable, 382 perhaps biological age or a marker of overall health, and further investigation is 383 384 required to identify what this variable might be and whether or not it can be modified 385 to minimise breast cancer risk. 386 387 A number of limitations are present in our work. The UK Biobank study, despite its sample size and almost comprehensive phenotyping, does have a "healthy volunteer" 388 389 selection bias. The rate of cancer is lower in comparison to the general population.<sup>30</sup> Also, the proportion of adults who were overweight or obese among men and women in 390 the UK population was 78% and 73%, respectively, compared to 74% and 60%, 391 respectively, for the same age group in the UK Biobank.<sup>31</sup> The sample is, therefore, not 392 393 representative of adiposity in the wider UK population. 394 In conclusion, we found that increased adiposity is causally protective for breast and 395 prostate cancer and the effects in the prostate cancer, at least partly, may be due to the 396 397 safe sequestration of chemicals in adipose cells. Further work needs to be done to identify variables that are responsible for the observed relationship between increased 398 BMI and increased risk of breast cancer. It is clear that reduction of adiposity, in and of 399 400 itself, may not reduce the risk of breast and prostate cancer as the recent campaign by Cancer Research UK<sup>3</sup> might suggest. It is necessary to explore the mechanisms through 401 402 which adiposity may protect against or be a risk factor for cancer, to identify how the 403 latter can be minimised without sacrificing the former, and to base public health campaigns around sound evidence. 404

405

# 406 **ACKNOWLEDGEMENTS**

- 407
- 408 We would like to thank the UKB staff and the UKB participants.

# 410 FUNDING

411

- 412 The work was supported by a Brunel Research Initiative and Enterprise Fund. HAA is the
- recipient of a PhD studentship from the College of Health and Life Sciences, Brunel
- 414 University London.

# 416 **DISCLOSURES**

- 417
- 418 The authors have no conflicts of interest to declare.

1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN

# 420 **REFERENCES**

421

422

estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: 423 424 A Cancer Journal for Clinicians 2018; 68: 394-424. . doi:10.3322/caac.21492 2. Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: 425 evidence from population-based patient-level data. British Journal of Cancer 2016; 426 427 114: 1286-1292. . doi:10.1038/bjc.2016.77 428 3. Cancer Research UK. Obesity, weight and cancer. 2019 429 4. Stone TW, McPherson M, Gail Darlington L. Obesity and Cancer: Existing and New Hypotheses for a Causal Connection. EBioMedicine 2018; 30: 14-28. 430 doi:10.1016/j.ebiom.2018.02.022 431 5. Gao C, Patel CJ, Michailidou K et al. Mendelian randomization study of adiposity-432 related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. Int J 433 434 Epidemiol 2016; 45: 896-908. . doi:10.1093/ije/dyw129 6. Guo Y, Andersen SW, Shu X et al. Genetically Predicted Body Mass Index and Breast 435 Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of 436 European Descent. PLOS Medicine 2016; 13: e1002105. 437 438 doi:10.1371/journal.pmed.1002105 7. Davies NM, Gaunt TR, Lewis SJ et al. The effects of height and BMI on prostate cancer 439 440 incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes Control 2015; 26: 441 1603-1616. doi:10.1007/s10552-015-0654-9 442 8. Iyengar NM, Arthur R, Manson JE et al. Association of Body Fat and Risk of Breast 443 444 Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary 445 Analysis of a Randomized Clinical Trial and Observational Study. JAMA Oncol 2019; 446 5: 155-163. . doi:10.1001/jamaoncol.2018.5327 447 9. Schoemaker MJ, Nichols HB, Wright LB et al. Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. JAMA Oncol 2018; 448 449 4: e181771. . doi:10.1001/jamaoncol.2018.1771 10. Harrison S, Tilling K, Turner EL et al. Systematic review and meta-analysis of the 450 451 associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes Control 2020. doi:10.1007/s10552-452 020-01291-3 453

between adiposity and cardiometabolic disease risk. Nature Communications 2016;

11. Lu Y, Day FR, Gustafsson S et al. New loci for body fat percentage reveal link

454

455

7: 1-15. . doi:10.1038/ncomms10495 456 12. Michailidou K, Lindström S, Dennis J et al. Association analysis identifies 65 new 457 458 breast cancer risk loci. Nature 2017; 551: 92-94. . doi:10.1038/nature24284 459 13. Schumacher FR, Olama AAA, Berndt SI et al. Association analyses of more than 460 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics 461 2018; 50: 928-936. . doi:10.1038/s41588-018-0142-8 462 14. Shungin D, Winkler TW, Croteau-Chonka DC et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 2015; 518: 187-196. . 463 doi:10.1038/nature14132 464 15. Locke AE, Kahali B, Berndt SI et al. Genetic studies of body mass index yield new 465 insights for obesity biology. Nature 2015; 518: 197-206. . doi:10.1038/nature14177 466 16. Sudlow C, Gallacher J, Allen N et al. UK biobank: an open access resource for 467 identifying the causes of a wide range of complex diseases of middle and old age. 468 PLoS Med 2015; 12: e1001779. . doi:10.1371/journal.pmed.1001779 469 470 17. Clare Bycroft, Colin Freeman, Desislava Petkova et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018; 562: 203-3... 471 472 doi:10.1038/s41586-018-0579-z 18. R Core Team. R: A language and environment for statistical 473 computing. https://www.R-project.org/ 2019 474 19. Chang CC, Chow CC, Tellier LC et al. Second-generation PLINK: rising to the challenge 475 476 of larger and richer datasets. Gigascience 2015; 4: 7. . doi:10.1186/s13742-015-0047-8 477 20. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for 478 479 Mendelian randomization. Stat Methods Med Res 2017; 26: 2333-2355. . 480 doi:10.1177/0962280215597579 481 21. Hemani G, Zheng J, Elsworth B et al. The MR-Base platform supports systematic 482 causal inference across the human phenome. Elife 2018; 7. doi:10.7554/eLife.34408 483 484 22. Chan DSM, Abar L, Cariolou M et al. World Cancer Research Fund International: Continuous Update Project-systematic literature review and meta-analysis of 485 observational cohort studies on physical activity, sedentary behavior, adiposity, and 486 487 weight change and breast cancer risk. Cancer Causes Control 2019; 30: 1183-1200. . doi:10.1007/s10552-019-01223-w 488

489 490 491	23. Perez-Cornago A, Appleby PN, Pischon T et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med 2017; 15: 115 doi:10.1186/s12916-017-0876-7
492 493 494	24. Rao GA, Mann JR, Bottai M et al. Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J Clin Pharmacol 2013; 53: 773-778 doi:10.1002/jcph.98
495 496 497	25. Lee Y-, Kim K-, Jacobs DR, Lee D Persistent organic pollutants in adipose tissue should be considered in obesity research. Obesity Reviews 2017; 18: 129-139 doi:10.1111/obr.12481
498 499 500 501	26. Jansen A, Lyche JL, Polder A et al. Increased blood levels of persistent organic pollutants (POP) in obese individuals after weight loss—A review. Journal of Toxicology and Environmental Health, Part B 2017; 20: 22-37 doi:10.1080/10937404.2016.1246391
502 503 504	27. Papadimitriou N, Dimou N, Tsilidis KK et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nature Communications 2020; 11: 1-10 doi:10.1038/s41467-020-14389-8
505 506 507	28. Lambert NG, ElShelmani H, Singh MK et al. Risk factors and biomarkers of age- related macular degeneration. Prog Retin Eye Res 2016; 54: 64-102 doi:10.1016/j.preteyeres.2016.04.003
508 509 510	29. Chmielewski PP, Strzelec B. Elevated leukocyte count as a harbinger of systemic inflammation, disease progression, and poor prognosis: a review. Folia Morphol (Warsz) 2018; 77: 171-178 doi:10.5603/FM.a2017.0101
511	30. Office for National Statistics. Cancer registration statistics, England: 2017. 2019
512	31. NHS Digital. Statistics on Obesity, Physical Activity and Diet, England, 2019. 2019

# 514 FIGURES

515

516 <u>Figure 1</u>

- 517 Odds ratios per SD increase (OR) and 95% confidence intervals when regressing incident
- 518 breast and prostate cancer cases on the adiposity measures using a logistic regression.
- 519 BMI = body mass index. BFP = body fat percentage. HC = hip circumference. WC = waist
- 520 circumference. WHR = waist-to-hip ratio.
- 521

Breast Prostate 1.1 0.8 0.9 1.0 OR



522

523

525 <u>Figure 2</u>

- 526 Odds ratios (OR) and 95% confidence intervals from a one-sample MR analysis of the
- 527 causal effect of adiposity on breast cancer risk. BMI = body mass index. BFP = body fat
- 528 percentage. HC = hip circumference. WC = waist circumference. WHR = waist-to-hip
- 529 ratio.
- 530





531 532

# 534 Figure 3

- 535 Odds ratios (OR) and 95% confidence intervals from a one-sample MR analysis of the
- causal effect of adiposity on prostate cancer risk. BMI = body mass index. BFP = body fat
- 537 percentage. HC = hip circumference. WC = waist circumference. WHR = waist-to-hip
- 538 ratio.
- 539



### ● All ▲ freq. chemical exposure ■ infreq. chemical exposure

541

540

# 543 **TABLES**

544

- 545 <u>Table 1</u>
- 546 Population characteristics. SD = standard deviation.

547

	males			females			
	all	controls	cases	all	control s	cases	
n	151940	145227	6713	174410	164974	9436	
age (SD), years	57.1 (8.08)	56.8 (8.1)	63 (4.88)	56.6 (7.9)	56.5 (7.92)	58.9 (7.1)	
BMI (SD), kg/m <sup>2</sup>	27.8 (4.22)	27.8 (4.24)	27.6 (3.83)	27 (5.14)	27 (5.15)	27.3 (4.93)	
% ever smoked	65.1	65	66.1	55.7	55.6	57.8	

548

# 550 <u>Table 2</u>

551 Odds ratios (OR) and 95% confidence intervals from a two-sample MR analysis of the

- causal effect of adiposity on breast cancer risk in women. U 95% CI = upper 95%
- 553 confidence interval. L 95% CI = lower 95% confidence interval.  $P^{(intercept)} = p$ -value of the
- intercept from the MR Egger method. BMI = body mass index. BFP = body fat
- 555 percentage. HC = hip circumference. WC = waist circumference. WHR = waist-to-hip
- 556 ratio.
- 557

Table 2							
Cancer	Exposure	Method	Р	OR	L 95% CI	U 95% Cl	P <sup>(intercept)</sup>
Breast	BMI	MR Egger	2.32E-05	0.444	0.321	0.616	0.00839
Breast	BMI	Inverse variance weighted	3.63E-08	0.683	0.596	0.782	NA
Breast	BFP	MR Egger	0.221	0.467	0.152	1.44	0.59
Breast	BFP	Inverse variance weighted	0.0215	0.63	0.425	0.934	NA
Breast	HC	MR Egger	0.00414	0.276	0.129	0.587	0.0236
Breast	HC	Inverse variance weighted	0.00725	0.689	0.525	0.904	NA
Breast	WC	MR Egger	3.64E-05	0.291	0.192	0.443	0.00124
Breast	WC	Inverse variance weighted	2.71E-05	0.643	0.523	0.79	NA
Breast	WHR	MR Egger	0.631	0.7	0.168	2.91	0.747
Breast	WHR	Inverse variance weighted	0.112	0.807	0.62	1.05	NA

558

# 560 <u>Table 3</u>

561 Od	ds ratios (	OR) and 95%	confidence inter	rvals from a two	o-sample MR	analysis of the
--------	-------------	-------------	------------------	------------------	-------------	-----------------

- 562 causal effect of adiposity on prostate cancer risk. U 95% CI = upper 95% confidence
- 563 interval. L 95% CI = lower 95% confidence interval.  $P^{(intercept)}$  = p-value of the intercept
- 564 from the MR Egger method. BMI = body mass index. BFP = body fat percentage. HC =
- 565 hip circumference. WC = waist circumference. WHR = waist-to-hip ratio.
- 566

Table 3							
Cancer	Exposure	Method	OR	L 95% Cl	U 95% CI	Р	$P^{(intercept)}$
Prostate	BMI	MR Egger	0.841	0.623	1.13	0.266	0.828
Prostate	BMI	Inverse variance weighted	0.815	0.73	0.91	0.000278	NA
Prostate	BFP	MR Egger	1.01	0.291	3.53	0.985	0.882
Prostate	BFP	Inverse variance weighted	0.921	0.696	1.22	0.563	NA
Prostate	HC	MR Egger	0.703	0.248	2	0.522	0.706
Prostate	HC	Inverse variance weighted	0.858	0.661	1.11	0.252	NA
Prostate	WC	MR Egger	1.39	0.203	9.53	0.745	0.664
Prostate	WC	Inverse variance weighted	0.801	0.604	1.06	0.123	NA
Prostate	WHR	MR Egger	0.482	0.183	1.27	0.277	0.23
Prostate	WHR	Inverse variance weighted	0.842	0.659	1.08	0.17	NA

567